NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
Recruiting · NCT06494514 · Interventional (participants receive a specific treatment) · Lead sponsor: Du Juan
View the official record on ClinicalTrials.gov →Interventions studied
Gemcitabine + albumin-paclitaxel+PD-1nal-IRI+Oxaliplatin+5-FU/LV+PD-1
What this trial is about
The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Histologically or cytologically confirmed pancreatic cancer;
- ECOG performance no more than 2;
- Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
- No previous anti-tumor therapy；
- Able and willing to provide a written informed consent;
Exclusion criteria
- 1\. Prior anti-tumor therapy of any kind; 2. Severe infection (\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.
Where it is running
2 locations listed.
- FirstNanjingMU - Nanjing, Jiangsu, China
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School - Nanjing, Jiangsu, China